Avoid Pitfalls
Costly Delays

Quality Research Partner from Idea to IND

Our expert drug discovery scientists help meet milestones and expedite your timeline to reaching development candidate, Investigational New Drug (IND) and ultimately to market.

Full Service Drug Discovery Contract Research Organization (CRO)

Confluence Discovery Technologies, Inc. (CDT), a wholly owned subsidiary of Aclaris Therapeutics, Inc., serves as research partners for pharma and biotech companies in cell and molecular biology, biochemistry, enzymology, biomarker development, immunology, in vivo efficacy models and medicinal chemistry. We specialize in drug discovery research on complex biological systems, challenging drug targets, immuno-oncology and preclinical and clinical biomarker development.

- Full Service -

Idea to IND

Access our experienced scientists and drug discovery leaders to expedite your project.

- Tailored -

Custom Research

Reach your goal with custom designed research by our experienced experts.

- Plug & Play -

Scientific Solutions

Select solutions from our unique multi‑platform assay options.

Experience & Expertise =


Lead Discovery

Clinical Candidate Selection

IND and Marketed Drug

Trusted By


Request Your Complimentary Consultation Now

Reach out to speak with an expert.

  • This field is for validation purposes and should be left unchanged.


"I've been very impressed with the enzymology and biochemical work that the Confluence team has provided."

—Director Biochemistry and Molecular Pharmacology, Cambridge Mass Biotech

"Thanks for the high-quality science you've offered in our collaborations. We look forward to continue working with you."

—Vice President Biochemical and Cellular Pharmacology, San Francisco Biotech

"I want to say "Thanks" to the Confluence team for your support of both our clinical and preclinical studies."

—Head of Pharmacology, MidWest Biotech

"Your team is great to work with."

—Preclinical Research and Early Development, Cambridge Mass Biotech

"Everything is going great on the Confluence collaborations. We definitely want to continue to work with your team."

—Director Biochemical and Cellular Pharmacology, San Francisco Biotech